ANXA7

Across TCGA pan-cancer cohorts, ANXA7 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ANXA7 data layer compared with 20 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher ANXA7 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ANXA7 expression acts as an unfavorable survival marker.

PAAD, BLCA, and SARC are the cancer types where ANXA7 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Median	All	0.112	0.613	<.001	24	view →
BLCA	OS	Median	III,IV	0.209	0.689	<.001	18	view →
SARC	OS	Median	All	0.156	0.767	.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ANXA7–PAAD (OS)

Open the PAAD breakdown →